Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer

Table 2

Multivariate analysis of factors affecting PSA recurrence-free survival.

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	-value	HR (95% CI)	-value
Age ≤ 70 y.o.	1.167 (0.707–1.926)	0.546
Initial PSA ≤ 20 ng/ml	0.610 (0.255–1.050)	0.074	0.795 (0.501–1.261)	0.329
T stage ≤ T2c	0.673 (0.292–1.156)	0.151
Gleason score ≤ 7	0.581 (0.332–0.018)	0.058	0.872 (0.594–1.281)	0.485
NCCN risk factor = 1	0.423 (0.242–0.741)	0.003	1.249 (0.766–2.036)	0.374
Anti-androgen +	0.602 (0.360–1.005)	0.052	1.036 (0.663–1.621)	0.876
Pre-RT PSA < 0.2 ng/ml	0.418 (0.249–0.702)	0.001	0.848 (0.580–1.240)	0.394
NAHT ≤ 6mo	0.730 (0.428–1.244)	0.247